It is estimated that 750,000 cases of severe sepsis occur in the United States
annually, at least 225,000 of which are fatal, resulting in significant utilization of
healthcare resources and expenses. Significant progress in the understanding of
pathophysiology and treatment of this condition has been made lately. Among the newer
treatment strategies for critically ill patients are the administration of early goal directed
therapy, and Recombinant Human Activated Protein C (Drotrecogrin alfa (activated)
[DTAA]) for severe sepsis. However, mortality remains unacceptably high.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.